Form 4: Cytokinetics CEO Robert Blum Sells 5,000 Shares

Cytokinetics' President and CEO, Robert I. Blum, sold 5,000 shares of common stock at a price of $36.77 on April 10, 2025.

Summary

• On April 10, 2025, Robert I. Blum, President & CEO and a Director of Cytokinetics Inc., sold 5,000 shares of common stock.
• The sale price was $36.77 per share.
• Following the transaction, Mr. Blum directly owns 422,629 shares of Cytokinetics common stock.
• He also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting an insider stock sale. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Insider sales are a common occurrence and are publicly disclosed to ensure transparency in the market. Investors often monitor these transactions for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The stock sale could potentially influence investor sentiment, although the impact is likely to be minimal given the relatively small number of shares sold compared to the total outstanding shares.

Key Dates

Keywords

Cytokinetics, Robert I. Blum, stock sale, Form 4, insider trading, CYTK, securities